Obermatt
See Similar Stocks →

Corvus Pharmaceuticals

NMQ:CRVS · US2210151005
BiotechnologySmall

360° View

no current rank
Price/Sales19
Price/Earnings84
Price/Book30
Dividend Yield—
Revenue Growth—
Profit Growth76
Capital Growth57
TSR 52w86
Leverage88
Liquidity7
Refinancing61
Combined—
Analyst Opinions72
Pro Holdings73
Opinion Changes50
Market Pulse80

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2014
Employees36
Websitecorvuspharma.com
ISINUS2210151005
Last UpdateApr 2, 2026
Index & Theme
AllergyImmunologyHematologyPulmonologyDermatologyRespiratoryOncologyBiopharmaBiotechnologyPharmaceutical

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops product candidates that precisely target proteins that are critical to immune cell maturation and function. The company’s lead product candidate, soquelitinib, is des…

Similar Stocks

The companies this stock is ranked against.

Compare Corvus Pharmaceuticals with its peers
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Shattuck Labs
NSQ:STTK
50
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Replimune Group
NSQ:REPL
1
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →